207 related articles for article (PubMed ID: 18764722)
1. Agents in development for the treatment of diabetic nephropathy.
Goh SY; Jasik M; Cooper ME
Expert Opin Emerg Drugs; 2008 Sep; 13(3):447-63. PubMed ID: 18764722
[TBL] [Abstract][Full Text] [Related]
2. New potential agents in treating diabetic kidney disease: the fourth act.
Williams ME
Drugs; 2006; 66(18):2287-98. PubMed ID: 17181372
[TBL] [Abstract][Full Text] [Related]
3. Investigational drugs for diabetic nephropathy.
Cortinovis M; Cattaneo D; Perico N; Remuzzi G
Expert Opin Investig Drugs; 2008 Oct; 17(10):1487-500. PubMed ID: 18808309
[TBL] [Abstract][Full Text] [Related]
4. Role of AGEs in diabetic nephropathy.
Fukami K; Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2008; 14(10):946-52. PubMed ID: 18473844
[TBL] [Abstract][Full Text] [Related]
5. The next generation of diabetic nephropathy therapies: an update.
Williams ME; Tuttle KR
Adv Chronic Kidney Dis; 2005 Apr; 12(2):212-22. PubMed ID: 15822057
[TBL] [Abstract][Full Text] [Related]
6. Novel approaches to the treatment of progressive renal disease.
Gilbert RE; Kelly DJ; Atkins RC
Curr Opin Pharmacol; 2001 Apr; 1(2):183-9. PubMed ID: 11714094
[TBL] [Abstract][Full Text] [Related]
7. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions.
Balakumar P; Arora MK; Ganti SS; Reddy J; Singh M
Pharmacol Res; 2009 Jul; 60(1):24-32. PubMed ID: 19427582
[TBL] [Abstract][Full Text] [Related]
9. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.
Tuttle KR; Anderson PW
Am J Kidney Dis; 2003 Sep; 42(3):456-65. PubMed ID: 12955673
[TBL] [Abstract][Full Text] [Related]
10. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes.
Coughlan MT; Forbes JM; Cooper ME
Kidney Int Suppl; 2007 Aug; (106):S54-60. PubMed ID: 17653212
[TBL] [Abstract][Full Text] [Related]
11. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.
Sourris KC; Forbes JM
Curr Drug Targets; 2009 Jan; 10(1):42-50. PubMed ID: 19149535
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy.
Forbes JM; Thallas-Bonke V; Cooper ME; Thomas MC
Curr Pharm Des; 2004; 10(27):3361-72. PubMed ID: 15544521
[TBL] [Abstract][Full Text] [Related]
13. The renin-angiotensin system and diabetic nephropathy.
Gurley SB; Coffman TM
Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Coughlan MT; Thallas-Bonke V; Pete J; Long DM; Gasser A; Tong DC; Arnstein M; Thorpe SR; Cooper ME; Forbes JM
Endocrinology; 2007 Feb; 148(2):886-95. PubMed ID: 17110423
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
16. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
17. The role of sulodexide in the treatment of diabetic nephropathy.
Weiss R; Niecestro R; Raz I
Drugs; 2007; 67(18):2681-96. PubMed ID: 18062718
[TBL] [Abstract][Full Text] [Related]
18. [Nephrotic syndrome due to metabolic disease--special reference to diabetic nephropathy].
Ohga S; Shikata K; Makino H
Nihon Rinsho; 2004 Oct; 62(10):1907-13. PubMed ID: 15500138
[TBL] [Abstract][Full Text] [Related]
19. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
Dalla Vestra M; Simioni N; Masiero A
Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapeutic strategies in diabetic nephropathy.
Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
